// App-Quantinova.ai

e13526 : Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi).

Researchers

Presenter

  • Bernhard Hauns

Principal Investigators

  • Henning Schulze-Bergkamen

  • Babett Krauss

  • Stefan W. Henning

  • Bernd Hentsch

  • Wilhelm Haverkamp

  • Dirk Jaeger

  • Hans-Georg Kopp

  • Michael Bitzer

Medical Centers

  • Department of Gastroenterology & Hepatology, Medical University Hospital, Tuebingen, Germany

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, GermanyDepartment of Hematology, Oncology and Immunology, University of Tuebingen, Tuebingen, GermanyCharite, Medizinische Klinik Kardiologie, Campus Virchow-Klinikum, Berlin, Germany

  • 4SC AG, Planegg-Martinsried, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Resminostat

Outcome

  • Positive

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • 4SC AG

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved